Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Niacinamide | 1 | 2025 | 32 | 0.890 |
Why?
|
| NAD | 1 | 2025 | 104 | 0.860 |
Why?
|
| Dietary Supplements | 2 | 2025 | 273 | 0.780 |
Why?
|
| Cognition | 2 | 2025 | 331 | 0.770 |
Why?
|
| Peripheral Arterial Disease | 1 | 2025 | 144 | 0.760 |
Why?
|
| Cognitive Dysfunction | 3 | 2024 | 271 | 0.490 |
Why?
|
| Mitochondria | 4 | 2025 | 410 | 0.250 |
Why?
|
| Neurovascular Coupling | 2 | 2024 | 154 | 0.240 |
Why?
|
| Endothelium, Vascular | 2 | 2025 | 334 | 0.230 |
Why?
|
| Pyridinium Compounds | 1 | 2025 | 27 | 0.230 |
Why?
|
| Endometrium | 4 | 1989 | 39 | 0.230 |
Why?
|
| Intrauterine Devices, Copper | 3 | 1989 | 3 | 0.220 |
Why?
|
| Administration, Oral | 1 | 2025 | 191 | 0.220 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 2067 | 0.210 |
Why?
|
| Aged | 5 | 2025 | 5608 | 0.200 |
Why?
|
| Pilot Projects | 1 | 2025 | 464 | 0.200 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2023 | 14 | 0.200 |
Why?
|
| White Matter | 1 | 2023 | 90 | 0.190 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2022 | 40 | 0.180 |
Why?
|
| Dementia | 1 | 2023 | 97 | 0.180 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 68 | 0.180 |
Why?
|
| Oxidative Stress | 1 | 2025 | 678 | 0.170 |
Why?
|
| Hypertension | 1 | 2023 | 309 | 0.160 |
Why?
|
| Female | 11 | 2025 | 15690 | 0.160 |
Why?
|
| Middle Aged | 3 | 2025 | 7428 | 0.150 |
Why?
|
| Uterine Neoplasms | 3 | 1988 | 80 | 0.140 |
Why?
|
| Humans | 13 | 2025 | 28998 | 0.140 |
Why?
|
| Medroxyprogesterone | 2 | 1988 | 4 | 0.130 |
Why?
|
| Male | 4 | 2025 | 13983 | 0.130 |
Why?
|
| Prolactinoma | 1 | 1992 | 1 | 0.090 |
Why?
|
| Pituitary Neoplasms | 1 | 1992 | 50 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 1004 | 0.080 |
Why?
|
| Uterus | 1 | 1989 | 31 | 0.070 |
Why?
|
| Pregnancy | 1 | 1992 | 1260 | 0.070 |
Why?
|
| Carcinoma | 1 | 1987 | 74 | 0.060 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2024 | 75 | 0.050 |
Why?
|
| Fasting | 1 | 2024 | 91 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 55 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 1 | 2024 | 225 | 0.050 |
Why?
|
| Bronchodilator Agents | 1 | 2022 | 15 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2022 | 45 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2023 | 93 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 41 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2022 | 42 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 75 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 1988 | 686 | 0.050 |
Why?
|
| Triglycerides | 1 | 2022 | 123 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 94 | 0.050 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2022 | 68 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2023 | 249 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 430 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2022 | 80 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 205 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2022 | 82 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 479 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2022 | 251 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 198 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 204 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 1283 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 843 | 0.040 |
Why?
|
| Microscopy, Electron | 2 | 1989 | 94 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 523 | 0.030 |
Why?
|
| Brain | 1 | 2023 | 770 | 0.030 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 1988 | 22 | 0.030 |
Why?
|
| Aging | 1 | 2024 | 1019 | 0.030 |
Why?
|
| Adenoma, Chromophobe | 1 | 1992 | 1 | 0.020 |
Why?
|
| Adenoma, Acidophil | 1 | 1992 | 1 | 0.020 |
Why?
|
| Sella Turcica | 1 | 1992 | 10 | 0.020 |
Why?
|
| Cesarean Section | 1 | 1992 | 55 | 0.020 |
Why?
|
| Dithizone | 1 | 1989 | 1 | 0.020 |
Why?
|
| Lipofuscin | 1 | 1989 | 7 | 0.020 |
Why?
|
| Actin Cytoskeleton | 1 | 1989 | 24 | 0.020 |
Why?
|
| Corrosion | 1 | 1989 | 37 | 0.020 |
Why?
|
| Copper | 1 | 1989 | 49 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 1992 | 924 | 0.020 |
Why?
|
| Erythrocytes | 1 | 1989 | 89 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1989 | 270 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1988 | 20 | 0.020 |
Why?
|
| Succinate Dehydrogenase | 1 | 1988 | 7 | 0.020 |
Why?
|
| Adult | 2 | 1992 | 8048 | 0.020 |
Why?
|
| Electron Transport Complex IV | 1 | 1988 | 40 | 0.020 |
Why?
|
| Brachytherapy | 1 | 1988 | 54 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1987 | 73 | 0.020 |
Why?
|
| Calcium | 1 | 1988 | 243 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 1987 | 303 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1987 | 612 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1988 | 300 | 0.010 |
Why?
|
| Cesium Radioisotopes | 1 | 1988 | 4 | 0.000 |
Why?
|